熱門資訊> 正文

Arcus Biosciences售价2.5亿美元

2025-10-31 12:40

Arcus Biosciences(RCUS) 0

Clinical-stage, global biopharmaceutical company Arcus Biosciences (RCUS) priced an underwritten public offering of 13.7M shares at $18.25 per share.
Gross proceeds are expected to be $250M.
The underwriters have a 30-day option to purchase up to 2.06M additional shares.
The offering is expected to close on November 3, 2025.
The stock price slumped 6% on Friday during pre-market hours of trading.

More on Arcus Biosciences

Arcus Biosciences: Refusing To Let The TIGIT Story Die, And Finding Potential Niches In Huge Markets
Arcus Biosciences, Inc. (RCUS) Shareholder/Analyst Call Transcript
Arcus Biosciences, Inc. (RCUS) Shareholder/Analyst Call - Slideshow
Arcus Biosciences rises on results from domvanalimab cancer study
Arcus Biosciences Q2 2025 Earnings Preview

推薦文章

風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。